...
首页> 外文期刊>Marine Drugs >Discovery of DNA Topoisomerase I Inhibitors with Low-Cytotoxicity Based on Virtual Screening from Natural Products
【24h】

Discovery of DNA Topoisomerase I Inhibitors with Low-Cytotoxicity Based on Virtual Screening from Natural Products

机译:基于天然产物的虚拟筛选发现低细胞毒性的DNA拓扑异构酶I抑制剂。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Currently, DNA topoisomerase I (Topo I) inhibitors constitute a family of antitumor agents with demonstrated clinical effects on human malignancies. However, the clinical uses of these agents have been greatly limited due to their severe toxic effects. Therefore, it is urgent to find and develop novel low toxic Topo I inhibitors. In recent years, during our ongoing research on natural antitumor products, a collection of low cytotoxic or non-cytotoxic compounds with various structures were identified from marine invertebrates, plants, and their symbiotic microorganisms. In the present study, new Topo I inhibitors were discovered from low cytotoxic and non-cytotoxic natural products by virtual screening with docking simulations in combination with bioassay test. In total, eight potent Topo I inhibitors were found from 138 low cytotoxic or non-cytotoxic compounds from coral-derived fungi and plants. All of these Topo I inhibitors demonstrated activities against Topo I-mediated relaxation of supercoiled DNA at the concentrations of 5–100 μM. Notably, the flavonoids showed higher Topo I inhibitory activities than other compounds. These newly discovered Topo I inhibitors exhibited structurally diverse and could be considered as a good starting point for the development of new antitumor lead compounds.
机译:目前,DNA拓扑异构酶I(Topo I)抑制剂构成了一系列抗肿瘤药物,已证明对人类恶性肿瘤具有临床作用。但是,由于它们的严重毒性作用,这些药物的临床用途受到很大限制。因此,迫切需要发现和开发新型的低毒性Topo I抑制剂。近年来,在我们对天然抗肿瘤产品的持续研究中,从海洋无脊椎动物,植物及其共生微生物中鉴定出了具有各种结构的低细胞毒性或非细胞毒性化合物。在本研究中,通过对接模拟与生物测定测试的虚拟筛选,从低细胞毒性和非细胞毒性天然产物中发现了新的Topo I抑制剂。总共从来自珊瑚的真菌和植物的138种低细胞毒性或非细胞毒性化合物中发现了八种有效的Topo I抑制剂。所有这些Topo I抑制剂在5-100μM的浓度下均表现出抗Topo I介导的超螺旋DNA松弛的活性。值得注意的是,类黄酮比其他化合物具有更高的Topo I抑制活性。这些新发现的Topo I抑制剂在结构上具有多样性,可以视为开发新的抗肿瘤先导化合物的良好起点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号